Abivax announces trading resumption of its ordinary shares on euronext paris

Paris, france / accesswire / october 20, 2023 / abivax sa (euronext paris:fr0012333284 - abvx) ("abivax" or the "company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on euronext in paris ("euronext paris") as from 4:20 p.m. cest.
ABVX Ratings Summary
ABVX Quant Ranking